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ABSTRACT
Objective: The objective of the study was to develop and validate a simple and reproducible reverse phase high pressure liquid chromatography (RP-
HPLC) method for hydrophilic drug isoniazid (INH) to apply for the analysis of the INH in nanoparticle drug formulations. Furthermore, to estimate 
simultaneously rifampicin (RIF) and INH in combined form.
Methods: Isocratic elution with 10 minutes runtime on a C-18 Luna, 5 µ, 100Å, 150 mm column, methanol, and water as mobile phase with detection 
wavelength at 268 nm was used. INH nanoformulations were prepared by double emulsion solvent evaporation technique. Quantitative analysis of 
encapsulated drug was estimated via developed RP-HPLC method. Simultaneous estimation for the two drugs was carried out by gradient elution. All 
chromatographic separation and estimations were obtained on Shimadzu HPLC system.
Results: INH eluted with a short retention time (RT) of 4.06 minutes. Method showed good linearity in the range of concentrations 0.01-100 µg/ml. 
The limit of detection (LOD) and quantification (LOQ) for INH was 0.03 and 0.12 µg/mL, respectively, and developed method has been successfully 
applied for the analysis of drugs in nanoparticle formulations. Simultaneous estimation of antitubercular drugs INH and RIF showed two separate 
peaks within specified runtime.
Conclusion: Developed method showed good resolved peaks. Since the RT is short, in a shorter duration more samples could be completed and 
developed method will be easy for analyzing greater number of samples. Analysis of nanoformulation results have shown that this method is simple, 
reliable, reproducible, hence can be applied for drug delivery analysis.
Keywords: Antitubercular drugs, Reverse phase high performance liquid chromatography, Analytical method development.
INTRODUCTION
An important step in nanoparticle drug delivery is the development 
of a simple and reproducible analytical method to analyze the drug 
concentrations. At present, reverse phase high pressure liquid 
chromatography (RP-HPLC) is the most effective and widely used 
technique for analyzing drugs in dosage forms and drug concentrations. 
In HPLC method development phase, all the parameters related to the 
method should be considered. Here, these parameters include choice 
of column, mobile phase, detectors, and method of quantitation. While 
developing new method best parameters should be selected [1]. In 
some cases, preferred elution or separation occurs with minimal 
experimentation. Some may require more number of experimental 
trials. Selection of best mobile phase, choice of column, detectors, 
stationary phase, column length, and column internal diameter plays 
important characters in HPLC method development steps. So process 
contains consideration of all these parameters pertaining to such 
method. In Reverse phase chromatography, common stationary phases 
in columns are the hydrophobic support that consists mainly of porous 
particles of silica gel in various shapes of various diameters and pore 
sizes. These particles surface is covered with many chemical entities, 
such as various hydrocarbons (C1, C6, C4, C8, C18, etc.) [2]. Compound 
which is more hydrophobic will be retained longer on the column than 
lesser hydrophobic one, based on the hydrophobicity they get separated. 
Organic and aqueous phases are the two components which are used 
as mobile phase [3]. As per “World Health Organization” reservation, 
INH is one the front line agent for the treatment of tuberculosis and 
INH pertains to the category of nucleoside reverse transcriptase 
inhibitor [4], with aqueous solubility of 140 mg/ml [5]. To determine 
polar compounds various analytical methods exists specifically for 
INH in literature [6]. Various other methods also have been described 
for determination and quantification of INH, such as H-point standard 
addition method [7], selective adsorption using a piezoelectric 
sensor [8], voltammetric method [9], amperometric method [10], 
chromatographic methods [11-14] (HPLC, GC and HPTLC), titrimetric 
methods [15], and chemiluminescence [16]. In addition, several 
(HPLC) methods for the simultaneous determination of rifampicin 
(RIF), INH, and pyrazinamide (PZA) in a fixed-dose combination [17] 
simultaneous analysis of RIF, INH and PZA in 0.1 M hydrochloric acid 
dissolution medium and in simulated gastric fluid [18], quantitative 
determination of INH in plasma, brain, liver and kidney samples and 
in solid lipid nanoparticles [19]. RIF and INH in combined dosage 
form estimation by UV spectrophotometric method [20,21] stability-
indicating high performance liquid chromatographic simultaneous 
determination of RIF, INH and PZA in human plasma [22] Most of the 
methods are time-consuming (long retention times [RT]) along with 
gradient methods. Simple isocratic RP-HPLC method is not available for 
determining quantitatively INH entrapped in polymer nanoparticles. 
TB treatment involves an initial 2 months’ therapy with combination 
of 4 drugs and subsequent 4 months with combination of both RIF 
and INH [23]. Since our work aimed to formulate this combination of 
INH and RIF (Fig. 1) [24] in nanoparticles, a simultaneous estimation 
of these two drugs becomes very important. However, there exist 
practical limitations, especially with regard to drug stability of RIF 
when estimated along with INH. Research to overcome these challenges 
in nanoformulation is being carried out.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i5.17582
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Here, a simple, precise, accurate, and reproducible RP-HPLC method 
has been developed and validated for the estimation and of hydrophilic 
drug INH and also simultaneous estimation of RIF and INH in combined 
form is shown in Fig. 1.
METHODS
Instrumentation
SHIMADZU Model No LC-20AD RP-HPLC system attached with 
Autoinjector SPD-20A and UV detector, LC solution software was used 
to record and integrate chromatograms, and the stationary phase 
column (phenomenex Luna C18, 4.6×150 mm, 5 µm, 100A°) was used 
for the analysis. Q Sonica - Sonicator Q -700 model, electronic balance 
(SHIMADZU AUW 220D), UV-1700-Visible Spectrophotometer 
Pharma Spec, Ultra Bath Sonicator from Grant Instruments UK, 
Magnetic stirrer (SCHOTT Instrument) Millipore Water purification 
system.
Materials and reagents
Poly(lactic-co-glycolic acid) (PLGA) 50:50 MW: 1,00,000-1,20,000 
Da was procured from Duret corporation AL USA, INH purchased 
from Himedia Ltd., Mumbai, Methanol (MERK Millipore Mumbai), 
Trifluroacetic acid (Loba Chemie, Mumbai, India) and all other reagents 
and chemicals were of HPLC grade. Polyvinyl alcohol (PVA) (87-89% 
hydrolyzed, MW: 1,20,000) procured from Thomas baker.
Experimental methods
Preparation of mobile phase
To establish a relevant HPLC method, couple of different mobile phases 
were attempted. The selection of mobile phase was decided based on 
the readily available solvents, short run time, results and sensitivity of 
assay. Mobile phases concluded here were aqueous solvent, i.e., MilliQ 
water and an organic solvent methanol. Solvents were filtered separately 
through 0.45 µm membrane filter and degassed by sonication.
Preparation of standard stock solution
About 10 mg of INH was weighed exactly and dissolved in 10 ml of 
water to make final concentration of 1 mg/ml.
Validation of the method
Method validation for developed RP-HPLC method was checked for 
linearity, specificity, precision, accuracy, and system suitability, LOD and 
LOQ as per the ICH guidelines [25].
Statistical analysis
Using Excel program, the method of least squares was calculated for the 
value of %relative standard deviation (RSD) and the linear regression 
analysis.
Analysis of isoniazid in nano formulations
Double emulsion solvent evaporation method was used to prepare 
INH nanoformulation. In brief, INH is dissolved in water and PLGA in 
dichloromethane. Primary emulsion was mixed with aqueous PVA solution 
to form a water-in-oil-in-water emulsion. Sonicated at 60% to form 
emulsion followed by solvent evaporation step. Repeated centrifugation 
was done to wash away the PVA at 13000 rpm. Pellet was re-dispersed in 
water, frozen overnight at −80°C and subjected to lyophilisation for 48 hrs 
to obtain powder form of the nanoparticles. We performed HPLC analysis 
using above developed method to know the amount of drug encapsulated 
in prepared nanoparticle formulation batches, 1 mg each INH loaded 
nanoparticles were weighed in triplicates. 1 ml methanol was added to 
each vial and placed on rocker shaker for 2d. Supernatant was collected 
after 2d. By centrifuging them at 10000 rpm for 20 minutes. Analyzed by 
developed RP-HPLC method and calculated for drug loading amount.
RESULTS AND DISCUSSION
Optimization and method development for isoniazid
INH was determined using RP-HPLC method, during the method 
development, many parameters with different combinations were 
tried, and different columns were assessed for RT, peak shape, and 
resolution of INH, after a number of trials, the method resulted with 
sharp clear peak with minimum tailing factor and short runtime was 
selected. INH eluted from the column at 4.06 minutes (Fig. 2) with flow 
rate of 1 ml/minutes using mobile phases, i.e., methanol and water 
(10:90). Analysis of INH was done with reverse phase phenomenex® 
Luna C18, 5 μ, 100A° 150 mm column in an isocratic mode with an 
injection volume 20 µl. Run time was set to 10 minutes, eluent seen at 
wavelength 268 nm. The method has been successfully applied for the 
analysis of the drug in nanoparticle drug formulations.
Linearity
It is an ability to attain test results that directly proportionate to 
the concentration of drug molecules present in the sample [26,27]. Fig. 1: Chemical structure of (1) isoniazid (2) rifampicin
Fig. 2: Chromatogram showing isoniazid peak at 4.06 retention time
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It is necessary to analyze within a suitable range for which 
the instrument’s response must be proportional to the drug 
concentration. Normally, value of co-relation coefficient (R2) >0.998 
is acceptable [28].
A series of calibration standards were made by diluting the stock 
solution appropriately using HPLC grade water to make solutions 
consisting INH in the concentration range of 0.01-100 µg/ml. Calibration 
graph was plotted by considering peak area versus concentration of the 
compound.
The linearity was evaluated by using linear regression analysis, which 
was calculated based on the least square regression method. Calibration 
curve with concentrations in tested range, found to be linear for INH. 
Peaks eluted at same RT 4.06 minutes and the high value correlation 
coefficient (R2) signified a good linearity since it was 1 (Fig. 3), where 
the correlation between the area of the peak and concentration is at 
good level. Lowest detection was found to be 0.03 µg/ml (Fig. 4) in a 
given range of concentrations.
Precision
With two levels (i.e., repeatability and intermediate) precision 
was determined, as mentioned in ICH recommendations. Sample 
application of repeatability was determined as intraday variation and of 
intermediate precision was determined as interday variation (Table 1).
Specificity
Ability to separate and to measure accurately the peak of interest 
indicates its specificity. This was checked by injecting replicates of INH 
standards and mixtures of INH and RIF.
There were clear separation and no additional peak in the 
chromatograms (Fig. 5), the % RSD for RT <0.5% indicate that the 
method developed is reproducible and has precision (Table 2).
System suitability
The system suitability test is used to ensure that the HPLC system and 
procedure are adequate for the analysis. For any method, the parameters 
of system suitability with their respective acceptance criteria should 
be a prerequisite. This will give an additional level of certainty that 
mobile phase, temperature, flow rate, and column used were proper 
and will ensure better system performance. This mostly includes least, 
a condition for injecting precision, sensitivity, and RT of the target 
analyte [29] HPLC system was stabilized for 30 minutes, with 3 blanks 
followed by 6 replicates of a single concentration of INH standard 
solution, injected to check the suitability of the system in this method. 
Parameters of this test were column efficiency (number of theoretical 
plates) asymmetry of chromatographic peak and reproducibility as RSD 
of the peak area of 6 injections of standard solutions. The peak area 
of %RSD and the drug RT were within 1% for entire samples (Table 3 
indicates the system suitability).
LOD and LOQ
In a sample, lowest concentration of an analyte which can be detected 
but quantification is not necessary under a given conditions of the 
experiment (LOD). LOQ in a sample is lowest concentration that can 
be analyzed with acceptable accuracy and precision under a given 
conditions of the analysis.
To calculate LOD and LOQ for validating the developed RP-HPLC 
method, equation applied were LOD = 3.3 σ/s and LOQ = 10 σ/s [30,31].
Also when standard solutions of INH was analyzed in range of 
0.01-100 µg/ml concentration the lowest detectable concentration was 
found to be 30 ng (Fig. 4).
Drug loading analysis in isoniazid polymeric nano formulations
Dry form of PLGA INH nanoparticles (67 mg) was obtained after 
lyophilization. The amount of drug encapsulated per mg of nanoparticles 
Table 1: Intra‑ and inter‑day precision of RP‑HPLC method for 
Isoniazid






Number of replicates* 3 3 3
SD 465 3795 10302




1,177,441 1,702,516 2,370,618 
Number of replicates* 3 3 3
SD 2763 1555 5912
%RSD# 0.23 0.93 0.25
RP-HPLC: Reverse phase high pressure liquid chromatography, *Average of 
3 determinations; # RSD: Relative standard deviation











RT: Retention time, SD: Standard deviation, RSD: Relative standard deviation, 
*Analysis of 6 determinations
was estimated using calibration curve substituting the area obtained 
via HPLC analysis (Table 4).
Fig. 3: (a) Calibration graph for isoniazid, (b) standard solutions 
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Similarly, method has been successfully applied for the analysis of drugs 
in different batches of nanoparticle drug formulations.
Simultaneous estimation of anti‑tubercular drugs
Analysis of RIF and INH were done with reverse phase phenomenex® 
Luna C18,5 μ, 100A° column in a gradient method. INH is a hydrophilic 
drug so initially when aqueous phase is more it elutes first with RT of 
3.5 minutes and slowly when organic mobile phase was increased RIF 
elutes at 15.5 minutes, this method shows separate 2 clear peaks with 
different RT. The eluents were seen at wavelength 290 nm for RIF and 
268 nm for INH (Fig. 6).
Calibration graph for simultaneous estimation of RIF and isoniazid
INH solution was done by diluting INH in water and RIF solution was 
made by diluting RIF in methanol to make primary solutions initially. 
Mixed the solutions by transferring 1 ml each from both the stock and 
vortexed to make final concentration of 1 mg/ml. Different standard 
solutions were prepared in the range of 10-100 µg/ml concentrations. 
Samples were vortexed and loaded to the autosampler and analyzed.
Equation of the curve was 79517x (R2 = 0.9982) for RIF and 42551x 
(R2 = 0.9996) for INH (Fig. 7), shows standard curves were found to be 
linear in the tested concentration range for RIF and INH. The R2 values 
specified the linearity was in the studied range.
From initial concentrations to last run when chromatograms were 
observed, we could able to see the extra peaks indicating degradation 
of RIF in simultaneous estimation (Fig. 8).
Fig. 4: Chromatogram showing peak of lowest detection 0.03 µg/ml
Fig. 5: Replicates of isoniazid standards showing specificity
Table 3: Results of System suitability
Samples* INH µg/ml
INH 10 µg/ml_01.lcd 4.06 3,28,053.00
INH 10 µg/ml_02.lcd 4.05 3,27,679.00
INH 10 µg/ml_03.lcd 4.06 3,28,836.00
INH 10 µg/ml_04.lcd 4.06 3,27,945.00
INH 10 µg/ml_05.lcd 4.06 3,28,454.00








SD: Standard deviation, LOD: Limit of detection, LOQ: Limit of quantification, 
RSD: Relative standard deviation, *Concentration and Area of 6 replicates of 
Isoniazid, #Analysis of 6 determinations
Table 4: Drug loading measurement of Isoniazid loaded PLGA 
nano formulation batch results
Batch Area (units) Encapsulation (amount of drug 
per mg of nanoparticle) (in µg)
1 278372 7.6
2 364582 10.05
Average=8.8±1.2 µg/mg, PLGA: Poly (lactic-co-glycolic acid)
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Fig. 6: Chromatogram showing 2 peaks at 2 different retention time
Fig. 7: Calibration graph for combination of drugs
Fig. 8: Chromatogram showing extra peaks in simultaneous 
estimation of INH and RIF
This data would be very useful in our further combination studies 
to build in quality, efficacy and safety in drug formulations are being 
carried out.
CONCLUSION
The analysis method developed for INH has shown good resolved 
peaks. Since the RT is short, it indicates that in a shorter duration more 
samples could be completed and developed method will be easy for 
analyzing larger samples. The values of LOD and LOQ for these both 
drugs were significantly low; hence, it can be concluded that this 
method is appropriate for detecting and quantifying the fairly low 
concentrations of these drugs. Results of statistical analysis, lower 
%RSD (i.e., <2.0%) values confirm the ability of the analytical assay. 
We have used it for Nanoparticle Encapsulation efficiency and release 
studies. Analysis of nanoformulation results have shown that this 
method is simple, reliable, precised, accurate, linear and reproducible, 
hence can be applied for drug delivery analysis. This method could be 
even suitable in active pharmaceutical preparations for quality control 
analysis.
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